Exelixis (NASDAQ:EXEL) Announces Quarterly Earnings Results, Misses Expectations By $0.04 EPS
Exelixis (NASDAQ:EXEL) Announces Quarterly Earnings Results, Misses Expectations By $0.04 EPS
Exelixis (NASDAQ:EXEL – Get Rating) released its earnings results on Tuesday. The biotechnology company reported ($0.09) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.05) by ($0.04), Briefing.com reports. The company had revenue of $423.92 million for the quarter, compared to the consensus estimate of $418.71 million. Exelixis had a return on equity of 13.11% and a net margin of 18.78%. The business's revenue was down 6.0% on a year-over-year basis. During the same quarter in the previous year, the company posted $0.29 EPS.
Exelixis(納斯達克：Exel-Get Rating)週二發佈了財報。據Briefing.com報道，這家生物技術公司公佈了本季度每股收益(EPS)(0.09美元)，低於(0.04美元)(0.05美元)的普遍預期。該公司本季度營收為4.2392億美元，而市場普遍預期為4.1871億美元。Exelixis的股本回報率為13.11%，淨利潤率為18.78%。該業務的收入同比下降了6.0%。去年同期，該公司公佈的每股收益為0.29美元。
Exelixis Price Performance
Exelixis性價比
NASDAQ:EXEL traded up $0.53 during mid-day trading on Wednesday, reaching $17.82. The stock had a trading volume of 1,101,195 shares, compared to its average volume of 2,793,073. Exelixis has a 12 month low of $14.87 and a 12 month high of $23.40. The stock has a market capitalization of $5.75 billion, a PE ratio of 18.53, a P/E/G ratio of 0.58 and a beta of 0.72. The stock has a 50-day simple moving average of $16.60 and a two-hundred day simple moving average of $17.26.
納斯達克：週三午盤交易中，Exel上漲0.53美元，至17.82美元。該股成交量為1,101,195股，而平均成交量為2,793,073股。Exelixis的12個月低點為14.87美元，12個月高位為23.40美元。該股市值57.5億美元，市盈率18.53倍，市盈率0.58倍，貝塔係數0.72。該股的50日簡單移動均線切入位為16.60美元，200日簡單移動均線切入位為17.26美元。
Wall Street Analyst Weigh In
華爾街分析師也加入進來
A number of brokerages recently weighed in on EXEL. Royal Bank of Canada lowered their target price on shares of Exelixis from $31.00 to $29.00 and set an "outperform" rating on the stock in a report on Wednesday, November 2nd. Piper Sandler reaffirmed an "overweight" rating and issued a $32.00 price objective on shares of Exelixis in a research report on Wednesday. EF Hutton Acquisition Co. I reissued a "buy" rating and set a $24.00 target price on shares of Exelixis in a report on Wednesday. Credit Suisse Group started coverage on shares of Exelixis in a research note on Thursday, January 26th. They issued an "outperform" rating and a $29.00 price target on the stock. Finally, Cowen decreased their price objective on Exelixis from $21.00 to $20.00 in a report on Monday, January 9th. One investment analyst has rated the stock with a hold rating and nine have given a buy rating to the stock. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus target price of $27.58.
一些券商最近加入了對Exel的看法。11月2日週三，加拿大皇家銀行在一份報告中將Exelixis的目標價從31.00美元下調至29.00美元，並對該股設定了“跑贏大盤”的評級。派珀·桑德勒在週三的一份研究報告中重申了對Exelixis的“增持”評級，並對Exelixis的股票發佈了32.00美元的目標價。EF Hutton Acquisition Co.I在週三的一份報告中重新發布了買入評級，併為Exelixis的股票設定了24.00美元的目標價。瑞士信貸集團在1月26日星期四的一份研究報告中開始對Exelixis的股票進行報道。他們對該股給予了“跑贏大盤”的評級和29.00美元的目標價。最後，考恩在1月9日星期一的一份報告中將Exelixis的目標價格從21.00美元下調至20.00美元。一名投資分析師對該股的評級為持有，九名分析師給予該股買入評級。根據MarketBeat的數據，該公司的共識評級為“適度買入”，共識目標價為27.58美元。
Insiders Place Their Bets
內部人士下注
Institutional Inflows and Outflows
機構資金流入和流出
A number of institutional investors have recently modified their holdings of EXEL. Toroso Investments LLC bought a new stake in shares of Exelixis in the third quarter valued at $198,000. Teachers Retirement System of The State of Kentucky purchased a new stake in shares of Exelixis in the third quarter worth $672,000. Captrust Financial Advisors boosted its stake in Exelixis by 167.4% during the third quarter. Captrust Financial Advisors now owns 15,766 shares of the biotechnology company's stock valued at $247,000 after buying an additional 9,871 shares during the period. Balyasny Asset Management LLC purchased a new position in Exelixis during the third quarter worth about $6,672,000. Finally, BNP Paribas Arbitrage SNC increased its stake in Exelixis by 17.0% in the 3rd quarter. BNP Paribas Arbitrage SNC now owns 214,537 shares of the biotechnology company's stock worth $3,364,000 after acquiring an additional 31,114 shares during the last quarter. Institutional investors and hedge funds own 84.74% of the company's stock.
一些機構投資者最近調整了對Exel的持股。Toroso Investments LLC在第三季度購買了Exelixis的新股份，價值19.8萬美元。肯塔基州教師退休系統在第三季度購買了價值672,000美元的Exelixis新股。CapTrust Financial Advisors在第三季度將其在Exelixis的持股增加了167.4%。CapTrust Financial Advisors現在擁有這家生物技術公司15,766股股票，價值24.7萬美元，在此期間又購買了9,871股。Balyasny Asset Management LLC在第三季度購買了Exelixis的一個新頭寸，價值約6,672,000美元。最後，法國巴黎銀行套利SNC在第三季度將其在Exelixis的持股增加了17.0%。法國巴黎銀行套利SNC現在持有這家生物技術公司214,537股票，價值336.4萬美元，在上個季度額外購買了31,114股票。機構投資者和對衝基金持有該公司84.74%的股票。
About Exelixis
關於Exelixis
(Get Rating)
(獲取評級)
Exelixis, Inc is a biopharmaceutical company, which engages in the development, commercialization, and discovery of new medicines for the treatment of cancer. It offers products under the brands of COMETRIQ, CABOMETYX, COTELLIC, and MINNEBRO. The company was founded by Corey S. Goodman and Stelios B.
Exelixis，Inc.是一家生物製藥公司，致力於癌症治療新藥的開發、商業化和發現。它提供COMETRIQ、CABOMETYX、COTELLIC和MINNEBRO品牌的產品。該公司是由科裏·S·古德曼和斯特利奧斯·B。
Featured Articles
專題文章
- Get a free copy of the StockNews.com research report on Exelixis (EXEL)
- TJX Among Apparel Retailers All Dressed Up & Ready For Growth
- Daqo New Energy Charged Up For New Highs
- No Spice In Chipotle Results, Is Now The Time To Buy?
- V.F. Corporation Is A High-Yield Bargain Despite Dividend Cut
- Fortinet's Earnings Rally is a Lesson in Market Expectations
- 免費獲取StockNews.com關於Exelixis的研究報告(Exel)
- 服裝零售商中的TJX都盛裝打扮，為增長做好了準備
- 大全新能源再創新高
- Chipotle結果中沒有香料，現在是買入的時候了嗎？
- 儘管削減了股息，V.F.Corporation仍是一筆高收益的交易
- Fortinet的盈利上漲是市場預期的教訓
Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.
接受Exelixis日報的新聞和評級-在下面輸入您的電子郵件地址，通過MarketBeat.com的免費每日電子郵件時事通訊接收對Exelixis和相關公司的最新新聞和分析師評級的每日簡要摘要。